Most recently, in September 2022, selpercatinib was granted regular approval for adult patients with locally advanced or metastatic NSCLC with a RET fusion and was granted accelerated approval for RET fusion–positive cancers in a tumor agnostic setting [19]. The gene discussed is RET; the disease is neoplasm.